Pharma BD Deal Intelligence
A durable but unspectacular bolt-on: gave Cephalon a real EU commercial footprint and one long-lived asset (Myocet), but the whole platform was subsumed six years later into Teva's $6.8B Cephalon buyout, making standalone ROI unmeasurable and never publicized as a standout success or failure.
Full analysis, sources & comparables →Cephalon agrees to acquire Zeneus for ~$360M cash, projecting ~$100M in additional 2006 sales and an instant European oncology footprint across 18 countries.
Cephalon paying $360M cash for Zeneus, gaining European oncology and supportive-care portfolio with Myocet, Targretin and Abelcet plus 245 commercial staff.
CEO Frank Baldino called the deal 'an excellent strategic fit'; PharmaTimes framed it as part of broader European specialty pharma consolidation, with profit…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Cephalon agrees to acquire Zeneus for ~$360M cash; European oncology platform with Myocet, Targretin, Abelcet. Closed Dec 22, 2005.
A durable but unspectacular bolt-on: gave Cephalon a real EU commercial footprint and one long-lived asset (Myocet), but the whole platform was subsumed six years later into Teva's $6.8B Cephalon buyout, making standalone ROI unmeasurable and never publicized as a standout success or failure.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Zeneus Holdings Limited (Zeneus Pharma) (this deal) | 2005 | $360M | 63 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
← Browse all deals · How we score deals
More: 2005 deals · Cephalon Inc. deals